SCHEMBL1131836

SCHEMBL1131836

C/C(=C\C(=O)O)c1cc(C2CCCCC2)n(-c2ccc(OCc3ccccc3)cc2)n1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MDM2 Q00987 2/20 0.46
BCL2 P10415 1/20 0.45
MCL1 Q07820 1/20 0.45
KDM4E B2RXH2 1/20 0.40
KMT2A Q03164 1/20 0.40
SMN1; SMN2 Q16637 1/20 0.40
KCNH2 Q12809 2/20 0.40
MCHR1 Q99705 2/20 0.40
CHRNB2 P17787 1/20 0.39
CHRNA5 P30532 1/20 0.39
CHRNA7 P36544 1/20 0.39
CHRNA4 P43681 1/20 0.39
CRACR2A Q9BSW2 1/20 0.39
LTB4R Q15722 2/20 0.39
LTB4R2 Q9NPC1 2/20 0.39
HRH3 Q9Y5N1 2/20 0.39
MAOB P27338 1/20 0.39
DHODH Q02127 1/20 0.39
RAB9A P51151 2/20 0.39
NPC1 O15118 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1132075 0.87 MDM2 (0.60) MDM2BCL2MCL1KDM4EKMT2A
SCHEMBL1131475 0.84 FAAH (0.52) MDM2BCL2MCL1KMT2AL3MBTL1
SCHEMBL1131253 0.84 SLC5A1 (0.38) CRACR2A
SCHEMBL1132048 0.84 MDM2 (0.45) MDM2BCL2MCL1KDM4EKMT2A
SCHEMBL1131660 0.84 MDM2 (0.45) MDM2BCL2MCL1KDM4EKMT2A
SCHEMBL1132002 0.82 KDM4E (0.43) MDM2BCL2MCL1KDM4EKMT2A
SCHEMBL1131756 0.82 KDM4E (0.43) MDM2BCL2MCL1KDM4EKMT2A
SCHEMBL1131668 0.82 KDM4E (0.44) MDM2BCL2MCL1KDM4EKMT2A
SCHEMBL1131667 0.82 KDM4E (0.44) MDM2BCL2MCL1KDM4EKMT2A
SCHEMBL1131017 0.80 MDM2 (0.43) MDM2BCL2MCL1KDM4EKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1663105-B1 CYCLOALKYL HETEROCYCLES FOR TREATING HEPATITIS C VIRUS BRISTOL MYERS SQUIBB CO (US) 2011-02-16 EP claimed
EP-1663105-B1 CYCLOALKYL HETEROCYCLES FOR TREATING HEPATITIS C VIRUS BRISTOL MYERS SQUIBB CO (US) 2011-02-16 EP disclosed